Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

  • Aptar Pharma

Aptar Pharma, a global leader in drug delivery systems, services and active packaging solutions, has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. This ready-to-use rescue treatment can be used when and where a seizure cluster occurs thanks to Aptar’s proven, intuitive and convenient Unidose Liquid System.

This approval again demonstrates Aptar’s expertise in developing patient-friendly drug delivery solutions to help pharmaceutical customers address unmet healthcare needs. Aptar offers a broad portfolio of innovative technologies and wide array of services to meet the highest quality standards of the pharmaceutical industry.

Proven Solution for Nasally Administered Treatments

Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily and can be administered by a non-healthcare professional to a patient during or after a seizure. During such an event, the patient or caregiver presses a small plunger on the bottom of the device to release the drug in a single spray into the nostril, where the drug can be quickly absorbed via the nasal mucosa.

Patented Unidose and Bidose Technology Platforms

Aptar’s Unidose and Bidose platforms are robust, primeless, and intuitive systems with 360° functionality and precise nasal drug delivery. These proven platforms offer biotech and pharmaceutical companies effective and reliable single or two-shot intranasal delivery for a variety of medicines including potential life-saving drugs and treatments of severe conditions. The devices can also integrate wireless connectivity technologies.

Accelerated Development Support via Aptar Pharma Services

This new rescue treatment for seizure activity is an example of a Combination Product submission, and benefited from Aptar Pharma’s services offering, a comprehensive portfolio of stage-specific development packages. Aptar’s dedicated Regulatory Affairs experts and analytical scientists help customers proactively address regulatory needs to accelerate and derisk approval.

“The launch of our Unidose System for this new U.S. FDA-approved nasal rescue treatment for seizure activity once again demonstrates Aptar Pharma’s ability to help our customers develop and launch complex treatments,” stated Gael Touya, President, Aptar Pharma. “Our proven nasal systems combined with our lab and analytical service capabilities create substantial value for our customers and help them secure approval. The ultimate end result is that we help expand life-saving treatments with our patient-friendly systems.”

See also

Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

Aptar Pharma, a leading drug delivery systems provider, is pleased to announce that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives for prescription and OTC products.

Aptar’s Nasal Unidose Device approved by US FDA

Aptar’s Nasal Unidose Device approved by US FDA

AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

Aptar Pharmas Freepod nasal spray device with GlaxoSmithKlines Otrivin wins prestigious WPO WorldStar 2019 award

Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

Aptar Pharma launches PureHale, a new portable and ready-to-use upper respiratory drug delivery solution

Aptar Pharma launches PureHale, a new portable and ready-to-use upper respiratory drug delivery solution

Aptar Pharma, a leading drug delivery systems provider, continues its commitment to meeting new market trends with the release of an industry first, PureHale, a new portable and ready-to-use drug delivery solution designed for upper respiratory care. PureHale is a revolutionary and intuitive device which – when used in combination with saline or other natural ingredient formulations – helps relieve the symptoms of upper respiratory system conditions.

Join Aptar Pharmas live webinar Good medicine: Solutions for sensitive injectable formulations

Join Aptar Pharma's live webinar "Good medicine: Solutions for sensitive injectable formulations"

Aptar Pharma, a leading provider of innovative drug delivery systems, will host a live educational webinar presenting the benefits of high quality film coated elastomeric components and the role they play in reducing patient and regulatory risk. Taking place on October 24, 2018, at 15.00 GMT, the webinar, entitled “Good Medicine: Solutions for Sensitive Injectable Formulations” will demonstrate how high quality film coated components meet compliance expectations while maintaining safety of supply for the drug product..

New technologies in ophthalmic drug delivery webinar hosted by Aptar Pharma

New technologies in ophthalmic drug delivery webinar hosted by Aptar Pharma

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced it will be hosting a live, complimentary webinar titled “Optimizing Patient Adherence and Compliance in Eye Care” on November 21 at 11AM EST. The webinar will offer expert insight from Matthias Birkhoff, Vice President Business Development at Aptar Pharma, and Dr. Degenhard Marx, Director Scientific Affairs within the Aptar Pharma Consumer Health Care Division.

Aptar Pharmas electronic lockout device approved by EMA

Aptar Pharma's electronic lockout device approved by EMA

Aptar Pharma, a world leader in innovative drug delivery systems, is pleased to announce the approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG. Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl®. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuardTM.

  • Jo Webb
  • Product Info
  • English
  • Created 23 Jan 2020
  • Modified 23 Jan 2020
  • Hits 153